Pam2-ODN protects against pneumonia in the presence of leukemia and chemotherapy. (A) Photograph of spleens. (B) GFP-positive cells at group allocation. (C) Survival of FBL3-engrafted mice following the indicated treatments, with or without. P. aeruginosa infection (10 mL of 2 × 10¹⁰ CFU/mL). (D) Bacterial burdens of the indicated organs at the time of death of mice from C. (E) Circulating leukocytes (top) and neutrophils (bottom) of FBL3-engrafted mice before and after high-dose chemotherapy at the time of group allocation. (F) GFP-positive cells for the samples in E. (G) Survival of FBL3-engrafted, chemotherapy-treated mice following the indicated treatments, with or without P. aeruginosa infection (10 mL of 2 × 10¹⁰ CFU/mL). (H) Bacterial burdens of the indicated organs at the time of death of mice from G. (A-D) and (E-H) each present a single experiment that is representative of ≥3 replicates. *P < .05 vs FBL3→PBS→P. aeruginosa. **P < .005 vs FBL3→PBS→P. aeruginosa. †P < .05 vs before chemotherapy.